For the quarter ending 2025-09-30, ALDX has $77,801,012 in assets. $28,556,469 in debts.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 59,340,599 | 41,241,269 | ||
| Marketable securities | 15,956,740 | 40,678,370 | ||
| Prepaid expenses and other current assets | 2,162,696 | 2,638,589 | ||
| Total current assets | 77,460,035 | 84,558,228 | ||
| Deferred offering costs | 0 | 0 | ||
| Right-of-use assets | 340,977 | 404,660 | ||
| Total assets | 77,801,012 | 84,962,888 | ||
| Accounts payable | 13,423 | 1,455,271 | ||
| Accrued expenses | 6,999,297 | 6,663,580 | ||
| Current portion of debt | 15,199,265 | 15,148,897 | ||
| Operating lease liabilities | 271,948 | 263,551 | ||
| Deferred collaboration revenue, long term | 6,000,000 | 6,000,000 | ||
| Total current liabilities | 28,483,933 | 29,531,299 | ||
| Operating lease liabilities, long-term | 72,536 | 143,447 | ||
| Long-term debt, net of current portion | 0 | 0 | ||
| Total liabilities | 28,556,469 | 29,674,746 | ||
| Common stock, voting, 0.001 par value 150,000,000 authorized and 60,162,773 and 59,648,278 shares issued and outstanding, respectively | 60,163 | 60,046 | ||
| Additional paid-in capital | 526,679,311 | 525,046,496 | ||
| Accumulated other comprehensive (loss) income | 815 | -10,995 | ||
| Accumulated deficit | -477,495,746 | -469,807,405 | ||
| Total stockholders equity | 49,244,543 | 55,288,142 | ||
| Total liabilities and stockholders equity | 77,801,012 | 84,962,888 | ||
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)